Jump to ContentJump to Main Navigation
Show Summary Details

Journal of Pediatric Endocrinology and Metabolism

Editor-in-Chief: Kiess, Wieland

Ed. by Bereket, Abdullah / Cohen, Pinhas / Darendeliler, Feyza / Dattani, Mehul / Gustafsson, Jan / Luo, Feihong / Mericq, Veronica / Roth, Christian / Toppari, Jorma

Editorial Board Member: Battelino, Tadej / Buyukgebiz, Atilla / Cassorla, Fernando / Chrousos, George P. / Cutfield, Wayne / Fideleff, Hugo L. / Hershkovitz, Eli / Hiort, Olaf / LaFranchi, Stephen H. / Lanes M. D., Roberto / Mohn, Angelika / Root, Allen W. / Rosenfeld, Ron G. / Werther, George / Zadik, Zvi


IMPACT FACTOR 2015: 0.912

SCImago Journal Rank (SJR) 2015: 0.493
Source Normalized Impact per Paper (SNIP) 2015: 0.600
Impact per Publication (IPP) 2015: 0.955

149,00 € / $224.00 / £112.00*

Online
ISSN
2191-0251
See all formats and pricing

 


Select Volume and Issue

Issues

A V59M KCNJ11 gene mutation leading to intermediate DEND syndrome in a Chinese child

1 / Guichen Ni1 / Yi Gu1 / Min Liu1

1Department of Endocrinology, National Key Discipline of Pediatrics (Capital Medical University), Ministry of Education, Beijing Children’s Hospital, Capital Medical University, Beijing, China

Corresponding author: Yanmei Sang, Department of Endocrinology, National Key Discipline of Pediatrics (Capital Medical University), Ministry of Education, Beijing Children’s Hospital, Capital Medical University, Beijing 100045, China Phone: +86-10-59616161-2302, Fax: +86-10-59718700

Citation Information: Journal of Pediatric Endocrinology and Metabolism. Volume 24, Issue 9-10, Pages 763–766, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: 10.1515/JPEM.2011.258, September 2011

Publication History

Received:
2011-08-16
Accepted:
2011-08-19
Published Online:
2011-09-17

Abstract

Heterozygous activating mutations in the KCNJ11 gene can cause permanent and transient neonatal diabetes. In the present study, we sequenced the KCNJ11 gene in a Chinese boy diagnosed with permanent neonatal diabetes mellitus (PNDM) and also in his parents. A heterozygous 175G>A (V59M) mutation was identified in the patient, while no KCNJ11 gene mutations were found in his parents, indicating that this mutation is de novo. The patient with the V59M mutation successfully switched from insulin injections to oral glibenclamide; 2 years of follow-up revealed that the patient had intermediate developmental delay, epilepsy and neonatal diabetes (DEND) syndrome. This is the first patient who is reported to have iDEND syndrome due to KCNJ11 V59M mutation in China.

Keywords: glibenclamide; KCNJ11; Kir6.2; neonatal diabetes

Comments (0)

Please log in or register to comment.